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ABSTRACT
Prediction and diagnosis of complex disease may not always be possible with a 
small number of biomarkers. Modern ‘omics’ technologies make it possible to cheaply 
and quantitatively assay hundreds of molecules generating large amounts of data from 
individual samples. In this study, we describe a parenclitic network-based approach 
to disease classification using a synthetic data set modelled on data from the United 
Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) and serological 
assay data from a nested set of samples from the same study. This approach allows 
us to integrate quantitative proteomic and categorical metadata into a single network, 
and then use network topologies to construct logistic regression models for disease 
classification. In this study of ovarian cancer, comprising of 30 controls and cases with 
samples taken <14 months to diagnosis (n = 30) and/or >34 months to diagnosis 
(n = 29), we were able to classify cases with a sensitivity of 80.3% within 14 months 
of diagnosis and 18.9% in samples exceeding 34 months to diagnosis at a specificity 
of 98%. Furthermore, we use the networks to make observations about proteins 
within the cohort and identify GZMH and FGFBP1 as changing in cases (in relation to 
controls) at time points most distal to diagnosis. We conclude that network-based 
approaches may offer a solution to the problem of complex disease classification that 
can be used in personalised medicine and to describe the underlying biology of cancer 
progression at a system level.
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INTRODUCTION
Personalised medicine is hailed as the next 
significant step in the treatment and monitoring 
of diseases. Some cancer treatments, for example 
Trastuzumab in HER-2 positive breast cancer, are already 
tailored to individuals based on personal expression data 
[1]. Given the rate at which technology is advancing 
for high-throughput molecular analysis, it is inevitable 
that samples will be routinely taken from a patient and 
analysed by a range of ‘omic technologies [2]. Whilst 
this will allow truly personalised medicine, there will 
be huge challenges in analysing large amounts of multi-
dimensional and longitudinal data. Given the technological 
advances of high-throughput, multi-omic technologies, a 
conceivable ideal would be to take all available data and 
identify changes that indicate an early stage malignancy 
or accurately predict the formation of such. The cancer 
genome atlas has shown that there are many possible 
combinations of changes responsible for the onset of 
particular cancer types [3]. Hence there is a need for a 
procedure that considers the changes in a system as a 
whole, i.e. a network biomarker. Herein, we present an 
algorithm for generating parenclitic networks that are 
optimised towards biomarker identification. The technique 
we present can also inform on the underlying biology [4], 
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as well as provide network models for prediction. Thus, 
we believe this could be an important progression in the 
advancement of personalised medicine.
Parenclitic networks, first described by Zanin et al. 
in 2014 [5, 6], are established by determining differences 
between pairs of analyte measurements (protein, mRNA 
etc.) in a control data set and individual case samples. If 
the difference is above a threshold, then a linkage between 
the analytes is created. This is repeated for every pair of 
analytes to generate a network. In [5], the differences were 
calculated by plotting a linear regression through a control 
population for a specific analyte pair and then calculating 
the perpendicular distance from the line of regression 
to the sample point for the same pair. We first show 
that a better approach, at least from the perspective of 
constructing a network-biomarker, is to use 2-dimensional 
kernel density estimation (2DKDE) as an underlying 
model for the control distribution. The difference is 
determined by the area under the density distribution in 
the controls for the sample marker-pair, thus if the sample 
marker pair lies in a region of low density, the area under 
the density distribution will be larger, and the inferred 
distance is greater. We have also developed the network 
approach to allow the inclusion of categorical as well as 
continuous data, allowing testing of cancer risk variables 
on the networks. In our approach, we take all available 
information and reduce it to network topological features 
that are then built into logistic regression models.
We apply the approach to the prediction of ovarian 
cancer (OC) using multiple protein measurements made 
in pre-diagnosis serum samples from a cohort of type II 
OC cases and matched controls. Ovarian cancer is the 6th 
most frequently occurring cancer in women and 10 year 
survival is only 35% for both Type I and Type II cancers 
combined [7]. Type II cancers are much more aggressive 
than Type I, and are responsible for the majority of deaths. 
Cancer antigen 125 (CA125) is the current best biomarker 
for OC, however it is only predictive in late stages of the 
disease when survival is between 5–19% [8]. A recent 
report from the UK Collaborative Trial of Ovarian Cancer 
Screening (UKCTOCS), which used serial serum CA125 
measurements, showed that whilst there was no significant 
benefit to mortality, there was a stage shift at diagnosis 
[9]. This supports that screening for OC may be a sensible 
approach in the future, but better models are required for 
earlier detection that will translate into improved mortality.
Herein, we employ parenclitic networks for disease 
prediction in a small cohort of ovarian cancer cases and 
controls at two time points with respect to clinical diagnosis. 
We also generate average (mode) networks for each time 
group that highlight differences in the protein-networks 
between cases and controls at these two time points.
RESULTS
Linkages between analytes in an individual are based 
on how the analyte pair is predicted to deviate from a 
control population. Zanin et al. [5] demonstrated that this 
can be performed by plotting a linear regression through 
a sample set of data and, for each individual, calculating 
the perpendicular distance (normalised by standard 
deviation (z-score)) from the regression for each analyte 
pair. To implement this in a general algorithm, one must 
assume that all pairs of analytes will be both correlative 
and follow a linear model. However, in biological samples, 
this is often not the case. For example, in Figure 1, we 
have plotted MUC16/CA125, an OC biomarker, against 
androgen receptor or folate receptor gamma, which form 
a non-correlative or a bimodal distribution respectively 
(Figure 1A, 1B). In neither case was the average distance 
able to differentiate between cases and controls. When 
repeating for all combinations of markers with MUC16, the 
mean P-value was 0.42 (SD = 0.31). We have overcome 
this by using 2-dimensional kernel density estimation to 
predict the density of two markers in a non-cancer control 
population. Sample deviation is determined based on 
the estimated density for the analyte pair (see methods 
and Supplementary Information (SI)). For the same 
combinations of markers, we were able to differentiate 
between cases and controls (Figure 1C and 1D) with a mean 
P-value of 3.17 × 10-7 (SD = 2.01 × 10-6). Therefore, we 
employed 2DKDE in our algorithm for linkage assignment.
Preliminary investigations with a longitudinal, 
synthetic data set modelled on CA125 (see Supplementary 
Information 2), showed that topological features of the 
networks can be used to detect changes within the data 
set (see Supplementary Figures 1, 2) at a given threshold. 
Not all topological features are maximally discriminative 
between cases and controls at the same threshold so 
we cycle through a number of thresholds to iteratively 
determine the optimum for each topological feature 
(Figure 2A and 2C, Supplementary Figures 3, 4). These 
descriptors can be combined into a multi-parameter 
logistic regression for disease prediction. We tested this 
procedure in an OC data set comprising type II OC cases 
and controls (n = 30), where each individual has two serum 
samples taken <14.5 months (late, n = 30) or >34.5 months 
(early, n = 29) prior to diagnosis. Protein quantification for 
each sample was performed by proximity extension assay 
for a panel of 92 cancer-related proteins (Olink Oncology 
II panel). A second data set, comprising 120 controls was 
also assayed with the same panel and used to generate the 
kernel density estimates (for further description of both 
data sets, see methods and Supplementary Tables 1-2). 
The best model for each time group generated using the 
parenclitic methodology was then compared with logistic 
models generated using the raw data (raw data logistic 
regression, RDLG) after Monte Carlo cross-validation. At 
a specificity of >98%, the best parenclitic model had a 
higher sensitivity in both early and late groups (Table 1). 
In the late group (<14 months to diagnosis), the 
best parenclitic model used “number of connections to 
MUC16” (Figure 2B), with the RDLG model using the raw 
values for MUC16. Whilst the sensitivity of the parenclitic 
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model (80.3%) was higher than the RDLG model 
(76.7%), suggesting that the parenclitic approach favours 
discrimination, there was no improvement on case/control 
discrimination within this data-set. (Figure 3A).
In the early group (>34.5 months to diagnosis), the 
parenclitic model comprised of alpha-centrality (Figure 
2D) and oral contraceptive pill (OCP) use (as a categorical 
variable), whereas in the RDLG model, glypican 1 (GPC1) 
was used. In this group, the higher sensitivity achieved 
for the parenclitic model (18.9%) compared to the 
RDLG model (16.3%) translated into 8 predicted cases 
in the parenclitic model, compared to 6 in the RDLG 
model (Figure 3B). Furthermore, of these, only 1 was 
diagnosed by both tests, suggesting that the parenclitic 
and RDLG models are identifying orthogonal features and 
combining them in a decision tree may provide improved 
discrimination at early time points.
Parenclitic networks can also be used to inform 
on changes within biological systems without the 
arbitrary cut off of a P-value or fold change. Thus, we 
generated a modal network to investigate differences 
between cases and controls and between the early and 
late OC groups. The modal network was produced by 
generating networks for each individual and taking the 
Figure 1: 2D-Kernal density estimation-based distance can differentiate cases (red circle) and controls (green triangle) 
where linear-regression based distance cannot. Linear regression was plotted using a control set (black crosses) for MUC16 vs 
AR (A) or MUC16 vs folate receptor gamma (B). Cases and controls are then overlaid and the perpendicular distance from each point 
determined. It was not possible to differentiate cases from controls using the linear regression (P = 0.999 or 0.198 for AR or folate receptor 
gamma respectively). 2DKDE estimation of the same distributions was performed (C and D) and distance calculated for each case and 
control based on the density of the underlying distribution. In both cases, it was possible to differentiate cases and controls in this manner.
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modal state of a linkage – i.e. if the modal state between 
any two markers was connected, they were connected 
in the modal-network. Networks were generated across 
a range of thresholds with community membership 
identified based on edge-betweenness clustering. Well 
connected markers are found in the centre of clusters 
and these “hub-centres” represent proteins that are the 
most different between cases and controls (Figure 4). 
In samples from the late group, i.e. closest to diagnosis, 
WDCF2 (HE4) and MUC16 (CA125) were clearly at 
the centre of the largest hub. Midkine (MK) was also 
well-connected in a subsidiary cluster, although it is not 
a clear hub-centre (Figure 4A). In samples taken furthest 
from diagnosis (early, >34.5 months), granzyme-H 
(GZMH) and fibroblast growth factor binding protein 
1 (FBF BP1) are well-connected centres and thus may 
indicate involvement in the onset of OC or response to 
tumorigenesis (Figure 4B). 
Figure 2: Parenclitic networks are generated across a range of thresholds. At each threshold, the network is described using 
a number of topological indices, the index value at each threshold is presented for connections to MUC16 (A) and alpha-centrality (C), 
which featured in prediction models for OC in the early, and late groups respectively. For each index, the smallest threshold that gives the 
greatest degree of differentiation between cases and controls was used to build the logistic regression models. For connections to MUC16, 
this was at a threshold of 90 (B) and for alpha-centrality, 50 was optimal (D). Red circles = cases, green triangles = controls, solid line = 
trend line. In A and C, the grey box is the optimal threshold; this data is shown in B and D.
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Whilst GO-term enrichment analysis shows that 
there is some enrichment for serine proteases within the 
group (data not shown), the protein pool is small and 
biased towards “cancer-related” proteins and consequently 
we do not hold much weight by this observation and have 
not investigated this further.
DISCUSSION
Parenclitic networks have been utilised for a number 
of approaches including both biological discovery [5] and 
cancer detection [4, 6]. In these cases, the methodology 
underlying edge/connection creation within the network has 
relied on multiple linear regression models. In biological 
data sets, the assumptions for performing a linear regression 
are not always met. In Figure 1, we provide examples of 
non-correlating and bimodal distributions in which distance 
from a linear regression between a disease-predictor 
(MUC16) and a non-predictor (AR, folate receptor gamma) 
is not able to differentiate between cases and controls. The 
method we have developed describes the data with a greater 
degree of fidelity by using 2DKDE and thus can achieve 
a better estimation of distance between an individual and 
a population. Indeed, we distinguished between cases and 
Table 1: Area under the ROC curve (AUC), specificity and sensitivity of the best performing parenclitic and RDLG 
models for early (>34.5 months to diagnosis) and late (<14.5 months to diagnosis) groups
























Models were generated using all combinations of 1, 2 or 3 markers and following cross-validation the best models were 
selected based initially on sensitivity and secondly on AUC. Specificity was set to be >98% and the maximum is reported 
for the given sensitivity. Models were generated by logistic regression of either the parenclitic topologies or raw data and 
model coefficients are provided.
Figure 3: Parenclitic-based models versus RDLG-models for late (A) and early (B) pre-diagnosis groups. The predicted value for 
each model is plotted with horizontal and vertical lines representing a diagnostic threshold giving 95% (dashed line) or 98% (solid line) 
specificity. Cases are represented by red circles and controls by green triangles, hence cases in the top left quadrant (grey square) were 
detected by the parenclitic-model only and cases in the bottom right quadrant by RDLG-models only. Points in the top right quadrant are 
detected by both models, OCP = oral contraceptive pill.
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controls for all pairs of distributions that included MUC16. 
The 2D density matrices require a large number of samples 
to describe the distribution accurately [10, 11], hence in 
this study, we used 249 independent control samples for 
deriving the density matrices and we would envisage that 
with fewer samples, this methodology would not work as 
effectively. This is being further investigated with synthetic 
data.
MUC16 (CA125) is currently the best diagnostic 
marker for OC, however, the specificity and sensitivity 
of the marker is hampered by elevated expression in a 
number of benign diseases and other cancer types [12]. 
Whilst the marker may be elevated at early stages of 
the disease, recent large studies of annual screening 
showed there was no improvement in mortality for those 
diagnosed from elevated CA125 or otherwise [13, 14]. In 
using a network approach, we hoped to be able to pick up 
on subtle changes in protein expression prior to diagnostic 
levels of CA125 [3]. As the data set was small, we aimed 
to avoid overfitting by limiting the number of possible 
markers in a logistic regression to 3 and cross-validated 
all results by the Monte Carlo method. At both time 
points, the parenclitic-based model had higher sensitivity 
than the best model generated from standard linear 
regression (Table 1). In the late group (close to diagnosis), 
this increase was marginal and the network-topological 
descriptor that features in the model was dependent on the 
expression of MUC16. Therefore it is unlikely that at time 
points closest to diagnosis we would be able to improve 
greatly upon current models that use this marker. In the 
networks, MUC16 was very highly connected close to 
diagnosis in cases, and this was also evident in the modal 
network (Figure 4A).
Mortality from OC is improved by diagnosis at 
earlier stages, therefore a test that can detect OC earlier 
is potentially of significant impact. In the raw data, we 
found that glypican-1 (GPC1) was the most predictive 
marker in the early (>34.5 months to diagnosis) group 
(sensitivity = 16.3%). GPC1 was recently identified as 
elevated in exosomes prepared from the serum of patients 
with pancreatic cancer [15] and may be involved in 
disease progression as a mediator of angiogenesis [16], 
although interestingly, a reduction of GPC1 was found to 
be predictive of disease in this case. Whilst the AUC was 
lower for the parenclitic model than the RDLG model, 
we did show improved sensitivity (sensitivity = 18.9%), 
a more clinically relevant measure, within this group and 
were able to detect a greater number of cases than the 
RDLG model. The best model found through the network 
topologies was reduced alpha-centrality (Figure 2D) 
combined with use of contraceptive pill as a categorical 
variable. Alpha-centrality is a universal measure of 
eigenvector centrality and is related to number of degrees 
(connections). Use of the contraceptive pill is known 
to reduce the risk of OC, particularly in non-BRCA1/2 
mutation carriers [17, 18].
Figure 4: Modal-networks represent the average networks for individuals at <14.5 months to diagnosis (A) or >34.5 months to diagnosis 
(B). Colours and shapes represent community membership as determined from clustering by edge-betweenness topology.
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In the early group (>34.5 months to diagnosis), we 
showed that the best parenclitic model and best RDLG 
model detected different cases, with only a single patient 
overlapping between them (Figure 3B). This raises 
the possibility of employing a decision-tree based test, 
and indeed, doing so within this data set would give a 
sensitivity of 48.3%. Whilst we do not have sufficient 
statistical power within this data set to validate this 
finding, it warrants further investigation.
Early stage OC is often asymptomatic, or symptoms 
are easily confused with other ailments and therefore it 
is usually diagnosed at a later stage when symptoms are 
more pronounced. In order to diagnose OC at earlier 
stages, a screening program coupled with surgery and 
chemotherapy may be successful [19]. With screening 
comes the opportunity to increase the power of statistical 
models for disease prediction by exploiting longitudinal 
models that consider an individual’s baseline. Combining 
parenclitic methodologies with longitudinal data analysis 
may provide further sensitivity. In our synthetic data-
set, modelled on CA125 in UKCTOCS, we observed 
immediate changes in a number of topological indices 
at the initiation of “cancer” (SF 2). In future, we hope to 
investigate longitudinal changes in the networks using real 
data-sets from UKCTOCS.
The power of parenclitic analysis is that as well as 
being compatible for use in predictive models, it may also 
be possible to investigate the underlying biology of cancer 
progression [5]. The advantages with using our parenclitic-
distance measure over conventional techniques is that it 
avoids the use of arbitrary fold-change or P-value cut-offs 
[20]. On the other hand, we do have to make a cut-off 
for distance thresholds and, although this is somewhat 
subjective, it is done with the advantage of seeing all the 
data represented in a single figure, allowing the researcher 
a greater level of insight when selecting the degree of 
network complexity. Model network analysis of OC in late 
stages highlighted MUC16 (CA125) and WFDC2 (HE4) 
as being responsible for most of the differences within the 
network (Figure 4A) and this is in line with these being 
the best reported serological markers of OC [21–24]. 
In the late-group network, there are two other clusters 
(blue or grey squares) in which MK is well-connected, 
although not an obvious hub-centre. Midkine is a growth 
factor with a diverse role in cell growth and development 
[25] as well as being a marker and potential mediator of 
cisplatin resistance [26, 27]. That all three proteins are 
well-connected within 14 months to diagnosis, but not at 
36 months, suggests their involvement in the progression 
of OC in response to early oncogenic events. Inhibition 
of MK in a number of tumor cell lines leads to reduced 
growth [28] and there is growing interest in this protein in 
a number of applications. The function of MK in ovarian 
cancer specifically is not well-understood, although its 
epigenetic modification in ovarian cancer cell lines has 
been linked to acquired cisplatin resistance [29]. Perhaps 
further investigation into the function of MK in ovarian 
cancer would be prudent.
In the early-group modal network, there was no single 
dominating hub. Whilst there was some enrichment of 
serine proteases in the connected proteins, the protein pool 
is small (93 proteins) and manually selected as “cancer-
related”, therefore, GO-term enrichment analysis provided 
no useful information. However, GZMH and FGFBP1 
are both well connected within the network, indicating 
their differential expression between cases and controls. 
GZMH has been reported as upregulated in some OC-tumor 
infiltrating leukocytes [30] as well as serologically in breast 
cancer [31] and this may be indicative of enhanced tumor-
specific leukocyte activity in the early stages of disease. 
FBFBP-1, to the knowledge of the authors, has not been 
reported as elevated during ovarian cancer, indeed staining 
could not be seen in histological samples of ovarian tissue 
held by the human protein atlas (https://www.proteinatlas.
org/ENSG00000137440-FGFBP1/tissue/ovary) [32]. It is, 
however, involved in cell proliferation and angiogenesis and 
is associated with a number of other cancers [33, 34]. Both 
GZMH and FGFBP1 would be interesting to investigate 
further in the context of early OC development. 
CONCLUSIONS
We have developed a novel method to generate 
parenclitic networks that uses high-fidelity 2D density 
distributions to measure the differences between co-
variables in a data set. Using topological indices achieved 
better discrimination of pre-diagnosis OC cases and 
controls than raw data logistic-regression models. Modal-
networks showed differences GZMH and FGFBP1 
between cases and controls at >34.5 months prior to 
diagnosis and they may be relevant in the development 
of OC. Parenclitic networks can be used in biomarkers 
models and improve upon the sensitivity of simple, linear 
regression-based models. In the context of ovarian cancer, 
we were able to detect, with a sensitivity of 18.3% and 
a specificity >98%, OC in individuals >34.5 months to 
diagnosis. Interestingly, the parenclitic-based and RDLG 
models diagnosed non-overlapping cases at early time 
points and this raises the option of validating a decision-
tree based method in a larger cohort. We aim to validate 
our current models in larger data sets for early detection 
of OC and postulate that this approach could be exploited 
in future data-driven personalised medicine.
MATERIALS AND METHODS
Sample set
A nested set of OC cases and controls were taken 
from the multi-modal screening arm of UKCTOCS as 
part of the Predicting Risk of Ovarian Malignancies, 
Improved Screening and Early detection (PROMISE) 
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study. UKCTOCS was approved by the Joint UCL/UCLH 
Research Ethics Committee A (Ref. 05/Q0505/57). Written 
informed consent was obtained from donors and no data 
allowing identification of patients was provided. Trial 
participants at enrolment were post-menopausal women 
aged 50-74 who had no family history of ovarian cancer. 
Women subsequently diagnosed with ovarian cancer were 
identified by cross-referencing with the Health and Social 
Care Information Centre cancer registry and death codes, 
with diagnosis confirmed by review of histopathology 
reports. Paired serum samples from 29 early (>34.5 
months to clinical diagnosis) and 30 late (<14.5 months 
to clinical diagnosis) type II OC cases (mostly high-grade 
serous) randomised to the multi-modal arm of UKCTOCS. 
Samples from 30 controls with no history of cancer were 
matched to cases by age (±5 years), collection date and 
collection centre. Epidemiological data (OCP use (ever), 
hormone replacement therapy use (at randomisation), 
body mass index and age) was available for these women. 
For more information, see Supplementary Tables 1–2. 
Single samples from an independent set of 249 non-cancer 
control women from UKCTOCS were also selected as 
base controls to build density distributions.
Serum protein measurements
Ninety two cancer-related analytes were measured 
in individual serum samples using Olink’s multiplex 
immunoassay Oncology II panel. Based on the proximity 
extension assay [35], this validated platform uses matched 
antibody pairs linked to DNA reporters. When binding to 
their target, the pair gives rise to amplicons which are 
quantified by RT-PCR, providing high sensitivity and 
accuracy. Known cancer antigens including MUC16, 
growth factors, receptors, angiogenic factors and adhesion 
regulators are measured [36]. Data was returned as log2-
transformed normalised expression values. 
Parenclitic network and model testing
For a detailed description of methods, see 
supplementary information. In brief, each subject/sample 
is represented by a graph (network) that includes both 
continuous and categorical data. Edges are set based on 
how pairs of covariates differ from a cloud of controls 
(base controls) by determining the distance based on 
two dimensional kernel density estimation (2DKDE). 
The greater the deviation of a pair of covariates from the 
region of greatest density in the base controls, the greater 
the distance. The inclusion of categorical-continuous data 
pairs is achieved by calculating the deviation from a set 
of base controls of the same categorical value. Once all 
distances are calculated, a threshold is applied so that 
only edges between deviating covariates remain, such that 
each subject/sample is represented by a graph of unique 
topology. Classification is then performed by combining 
indices of topology into logistic regression models with 
performance being assessed by sensitivity at >98% 
specificity and the area under the ROC curve (AUC). The 
top 5 parenclitic and RDLG models (selected based on 
sensitivity and then AUC) were further validated by Monte 
Carlo cross-validation by splitting the data 50/50 100 
times. All analysis was performed in R Studio (1.0.143) 
running R version 3.4.0. Networks were generated using 
the igraph package (version 1.0.1).
Modal-network construction
Modal networks were derived by generating 
parenclitic networks for each sample at a range of 
thresholds. For each threshold, the networks were combined 
into a single network where nodes are connected, if they 
were connected in more than half of the individual networks 
(i.e. the modal stage of connectedness). The analytes were 
then clustered using the cluster_edge_betweenness function 
in the igraph package (version 1.0.1) and community 
membership determined based on maximum modularity 
score in the same function.
Abbreviations
2DKDE: 2-dimensional kernel density estimation 
(2DKDE); OC: ovarian cancer; CA125/MUC 16: cancer 
antigen 125; UKCTOCS: United Kingdom Collaborative 
Trial of Ovarian Cancer Screening; RDLG: raw data 
logistic regression; OCP: oral contraceptive pill; ROC: 
receiver operating characteristic; AUC: area under the 
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